Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
Background Early recurrence of hepatocellular carcinoma (HCC) is a major obstacle to improving the prognosis, and no widely accepted adjuvant therapy guideline for patients post-liver resection is available. Currently, all available methods and biomarkers are insufficient to accurately predict post-...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
PeerJ Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3e08f6c374c74528b081541cbed5fc68 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sea el primero en dejar un comentario!